A-CAR028

N/A

Report date: 2025/10/10 20:01:49

Base Information

Drug NameA-CAR028
Drug Alias NameA-CAR028
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMyeloid cell surface antigen CD33 modulatorsC-Type lectin domain family 12 member A modulatorsT lymphocyte replacements
TargetsMyeloid cell surface antigen CD33C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCellular Biomedicine (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCellular Biomedicine (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A